CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 123 filers reported holding CYMABAY THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is 0.29 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $307,474 | -31.3% | 20,622 | -49.6% | 0.00% | – |
Q2 2023 | $447,647 | +8194.4% | 40,881 | +6504.4% | 0.00% | – |
Q1 2023 | $5,397 | +60.3% | 619 | +15.3% | 0.00% | – |
Q4 2022 | $3,367 | +12.2% | 537 | -23.2% | 0.00% | – |
Q3 2022 | $3,000 | 0.0% | 699 | -1.4% | 0.00% | – |
Q2 2022 | $3,000 | -90.3% | 709 | -92.8% | 0.00% | – |
Q1 2022 | $31,000 | -70.5% | 9,859 | -68.2% | 0.00% | – |
Q4 2021 | $105,000 | +556.2% | 30,981 | +638.2% | 0.00% | – |
Q3 2021 | $16,000 | -91.8% | 4,197 | -90.5% | 0.00% | – |
Q2 2021 | $194,000 | -81.0% | 44,324 | -80.3% | 0.00% | – |
Q1 2021 | $1,021,000 | -1.5% | 224,942 | +24.4% | 0.00% | – |
Q4 2020 | $1,037,000 | +181.0% | 180,781 | +254.3% | 0.00% | – |
Q3 2020 | $369,000 | +64.7% | 51,023 | -20.4% | 0.00% | – |
Q2 2020 | $224,000 | +234.3% | 64,090 | +41.5% | 0.00% | – |
Q1 2020 | $67,000 | -29.5% | 45,308 | -6.4% | 0.00% | – |
Q4 2019 | $95,000 | -78.7% | 48,397 | -44.4% | 0.00% | – |
Q3 2019 | $446,000 | -11.5% | 87,053 | +23.6% | 0.00% | – |
Q2 2019 | $504,000 | -72.9% | 70,458 | -49.6% | 0.00% | -100.0% |
Q1 2019 | $1,858,000 | +66.5% | 139,935 | -1.4% | 0.00% | – |
Q4 2018 | $1,116,000 | -26.9% | 141,856 | +2.9% | 0.00% | – |
Q3 2018 | $1,527,000 | +23.8% | 137,793 | +50.0% | 0.00% | – |
Q2 2018 | $1,233,000 | +80.0% | 91,864 | +74.2% | 0.00% | – |
Q1 2018 | $685,000 | +90.3% | 52,723 | +34.7% | 0.00% | – |
Q4 2017 | $360,000 | +8900.0% | 39,146 | +7729.2% | 0.00% | – |
Q3 2017 | $4,000 | – | 500 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Saturn V Capital Management LP | 1,629,464 | $14,208,926 | 10.61% |
Lynx1 Capital Management LP | 1,369,927 | $11,945,763 | 9.96% |
Versant Venture Management, LLC | 543,753 | $4,741,526 | 9.88% |
Foresite Capital Management IV, LLC | 1,787,094 | $15,583,460 | 8.09% |
Octagon Capital Advisors LP | 4,570,918 | $39,858,405 | 5.74% |
ACUTA CAPITAL PARTNERS, LLC | 878,500 | $7,660,520 | 5.64% |
TCG Crossover Management, LLC | 3,048,257 | $26,580,801 | 5.18% |
Affinity Asset Advisors, LLC | 1,083,118 | $9,444,789 | 3.12% |
Altium Capital Management LP | 620,000 | $5,406,400 | 3.00% |
Bain Capital Life Sciences Investors, LLC | 2,500,000 | $21,800 | 2.72% |